AUTHOR=Xiao Guanglin , He Taiyu , Zhang Biqiong , Yang Ziqiao , Ling Ning , Chen Min , Zhang Dazhi , Hu Peng , Zhang Gaoli , Peng Mingli , Cai Dachuan , Ren Hong 

TITLE=Safety and Efficacy of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases: A Systematic Review and Meta-Analysis

JOURNAL=International Journal of Public Health

VOLUME=Volume 69 - 2024

YEAR=2024

URL=https://www.ssph-journal.org/journals/international-journal-of-public-health/articles/10.3389/ijph.2024.1605295

DOI=10.3389/ijph.2024.1605295

ISSN=1661-8564

ABSTRACT=Objectives: This review aimed to assess the safety and efficacy of SARS-CoV-2 vaccines in patients with chronic liver disease (CLD).
Methods: Cochrane Central Register of Controlled Trials, PubMed, Embase, and Web of Science were searched from 2020 to 2024. Data was extracted following Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines. The random-effects model (when I²≥50%) or fixed effect model (I²＜50%) was used.
Results: 29 studies were included in this review. Compared to healthy controls (HCs), patients with CLD had a higher incidence of mild adverse events (RR=1.60, p<0.001), while the incidence of severe adverse events was similar (RR=1.08, p=0.92). Seropositivity rates of three antibodies in patients were lower than in HCs [neutralizing antibody (RR=0.86, p=0.002), anti-spike antibody (RR=0.97, p=0.06) and anti-receptor binding domain antibody (RR=0.95, p=0.04)]. Compared to unvaccinated patients, vaccinated patients had lower rates of SARS-CoV-2 infection, hospitalization and death (p≤0.05).
Conclusions: SARS-CoV-2 vaccines showed good safety and efficacy in CLD patients, but antibody response appeared to be decreased. Therefore, SARS-CoV-2 vaccines and booster doses should be given priority in this vulnerable population.